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dietary supplementation of crude lecithin for 2–3 weeks. The 
aim was to provide experimental evidence for the hypothe-
sized additive effects of dietary lecithin (not containing any 
DHA) on top of dietary DHA on PUFA levels in plasma 
and RBC. Dietary supplementation of DHA-containing oils, 
either as vegetable algae oil or as fish oil, increased DHA, 
eicosapentaenoic acid (EPA), and total n-3 PUFA, and 
decreased total omega-6 PUFA levels in plasma and RBC, 
while dietary lecithin supplementation alone did not affect 
these levels. However, combined dietary supplementation of 
DHA and lecithin increased the changes induced by DHA 
supplementation alone. Animals receiving a lecithin-con-
taining diet also had a higher plasma free choline concentra-
tion as compared to controls. In conclusion, dietary DHA-
containing oils and crude lecithin have synergistic effects 
on increasing plasma and RBC n-3 PUFA levels, including 
DHA and EPA. By increasing the systemic availability of 
dietary DHA, dietary lecithin may increase the efficacy of 
DHA supplementation when their intake is combined.
Keywords Phospholipids · Docosahexaenoic acid · 
Plasma lipids · n-3 Fatty acids · Nutrition · Fish oil · Algal 
lipids
Abbreviations
DHA  Docosahexaenoic acid
EPA  Eicosapentaenoic acid
GC  Gas chromatography
HPLC  High performance liquid chromatography
MUFA  Monounsaturated fatty acid(s)
n-3  Omega-3
n-6  Omega-6
PUFA  Polyunsaturated fatty acid(s)
PtdCho  Phosphatidylcholine
PtdEtn  Phosphatidylethanolamine
Abstract Crude lecithin, a mixture of mainly phospho-
lipids, potentially helps to increase the systemic availability 
of dietary omega-3 polyunsaturated fatty acids (n-3 PUFA), 
such as docosahexaenoic acid (DHA). Nevertheless, no 
clear data exist on the effects of prolonged combined dietary 
supplementation of DHA and lecithin on RBC and plasma 
PUFA levels. In the current experiments, levels of DHA and 
choline, two dietary ingredients that enhance neuronal mem-
brane formation and function, were determined in plasma 
and red blood cells (RBC) from rats after dietary supplemen-
tation of DHA-containing oils with and without concomitant 
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PtdIns  Phosphatidylinositol
RBC  Red blood cell(s)
SFA  Saturated fatty acid(s)
Introduction
Omega-3 polyunsaturated fatty acids (n-3 PUFA), such 
as docosahexaenoic acid (DHA), are important structural 
components of neuronal membranes and are function-
ally implied in various membrane-bound processes [1, 2]. 
Dietary supplementation of n-3 PUFA raises blood n-3 
PUFA levels rapidly [3, 4] and increases their uptake into 
the brain and therefore their availability for incorporation 
into neuronal membranes [5, 6]. Thus, neuronal membrane 
structure and function are subject to alterations induced by 
nutritional compounds such as n-3 PUFA.
As a result of its biochemical and biophysical proper-
ties, dietary lecithin may help to increase the availability 
of dietary n-3 PUFA, with subsequent effects on neuronal 
membrane structure and function. Crude lecithin is a mix-
ture of mainly phospholipids (up to approximately 75 % 
for de-oiled lecithin), i.e., phosphatidylcholine (PtdCho), 
phosphatidylethanolamine (PtdEtn), and phosphatidylino-
sitol (PtdIns), and a smaller fraction of glycolipids, neutral 
lipids, and carbohydrates, that can be extracted from plant 
or animal food substances. Lecithin has low solubility in 
water, but is a very good emulsifier and is also a source of 
active compounds, such as choline, that can be released 
from PtdCho. Theoretically, dietary lecithin (i.e., phos-
pholipids) could increase systemic availability of dietary 
n-3 PUFA, since (biliary) phospholipids are required for 
the absorption of fat from the gut lumen into the entero-
cytes and the lymph [7, 8]. Several preclinical studies 
have examined the potential additive effects of lecithin or 
phospholipids on the bioavailability of triglycerides after 
oral intake [9–15]. However, most of these studies inves-
tigated (1) post-prandial effects of a single dose and/or (2) 
effects on lymphatic accretion and/or (3) effects of emul-
sification, i.e., whether pre-emulsifying oil with lecithin 
enhances the oil’s bioavailability. For example, recently 
Couëdelo et al. showed in rats that the lymphatic accretion 
after single intra-gastric administration of an oil containing 
the omega-3 fatty acid alpha-linolenic acid (ALA) could 
be increased by pre-emulsifying the oil with lecithin [14]. 
No distinct data exist on the effects of prolonged combined 
dietary supplementation of n-3 PUFA, especially DHA, and 
phospholipids on plasma and red blood cell (RBC) PUFA 
levels. Systemic availability is functionally relevant as the 
availability of n-3 PUFA to tissues such as the brain is 
largely dependent on their levels in circulation.
The objective of the present study was to test the hypoth-
esized additive effects of dietary crude lecithin (which 
itself does not contain DHA) on top of dietary supplemen-
tation with DHA-containing oils. Experimental diets were 
presented to rats for 2–3 weeks after which relative and 
quantitative plasma levels and relative RBC levels of DHA, 
eicosapentaenoic acid (EPA), total n-3 PUFA, and total 
omega-6 (n-6) PUFA were determined. Plasma choline was 
measured to confirm that dietary lecithin, being a source of 
PtdCho, increases plasma choline concentration.
Materials and Methods
To investigate the effects of dietary lecithin on the systemic 
availability of dietary DHA in adult rats, two experiments 
were conducted at the Centrum Kleine Proefdieren, Wagen-
ingen University (Wageningen, The Netherlands).
Animals
Twenty-four male Wistar rats (HsdCpb:WU) (Experiment 
A) and 24 Sprague–Dawley rats (Hsd:SD) (Experiment B) 
were obtained from Harlan (Harlan Nederland, Horst, The 
Netherlands). Animals aged 10 weeks on arrival were housed 
in groups in a temperature- and light-controlled room, 
under 12 h light–12 h dark cycles. Rats had free access to 
experimental diets and water. Body weight and food-intake 
was recorded at least once a week. All experimental proto-
cols were conducted in accordance with international and 
national laws and institutional guidelines and approved by 
the local ethics committee [DEC Consult, Bilthoven, The 
Netherlands, protocol numbers DEC Nr. NR117 (Experi-
ment A) and DEC Nr. DAN0190 (Experiment B)].
Diets
In Experiment A, four grain-based experimental diets with 
varying levels of vegetable algae DHA oil and crude leci-
thin were used: (1) control; (2) lecithin; (3) vegetable DHA 
oil; (4) vegetable DHA oil + lecithin. In Experiment B, 
three AIN-93M-based diets were used with varying levels 
of fish oil and crude lecithin: (1) control; (2) fish oil; (3) 
fish oil + lecithin. Within each experiment the diets were 
isocaloric and identical with respect to their protein, car-
bohydrate, fiber, and mineral contents. The diets fulfilled 
minimal dietary requirements for rats and were presented 
to the animals as pellets. The diets differed in composition 
with regard to the fat blends used, as well as the amount 
of lecithin added. The control diets and the lecithin diet 
did not contain DHA or EPA and the control diets did not 
contain any added crude lecithin. The lecithin-containing 
diets in Experiment A were supplemented with 400 mg 
de-oiled crude soy lecithin/100 g diet (0.4 %, Emulpur IP, 
Cargill Texturizing Solutions, The Netherlands), whereas 
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the amount of de-oiled crude lecithin added to the lecithin-
containing diet in Experiment B was 1000 mg/100 g diet 
(1.0 %). Average daily intake of crude lecithin per body 
weight was calculated based on the respective measured 
average body weight and food intake and was approxi-
mately 250 mg crude lecithin/kg BW/day (Experiment A) 
and 550 mg crude lecithin/kg BW/day (Experiment B). 
The de-oiled soy crude lecithin mainly contained phospho-
lipids (77 g phospholipids/100 g lecithin) of which mainly 
PtdCho (20 g/100 g lecithin), PtdIns (14 g/100 g lecithin), 
and PtdEtn (13 g/100 g lecithin, as provided by the sup-
plier), with mainly linoleic acid (18:2n-6), palmitic acid 
(16:0), and oleic acid (18:1n-9), and did not contain any 
DHA. The total fat content of the fish oil + lecithin diet 
in Experiment B was corrected for the fat content of the 
added lecithin. In Experiment A, the amount of fat from 
lecithin was considered to be negligible. The DHA content 
of the diets containing vegetable algae DHA oil (DHASCO 
oil, Martek Biosciences Corporation, USA) in Experiment 
A and the diets containing fish oil (Tuna RoPUFA, Nu-
Mega, Australia) in Experiment B was equal and moder-
ate, namely 0.2 DHA g/100 g. Average daily intake of the 
DHA per body weight was calculated based on the respec-
tive measured average body weight and food intake and 
was approximately 125 mg DHA/kg BW/day (Experiment 
A) and 110 mg DHA/kg BW/day (Experiment B). Average 
daily intake of the EPA per body weight was approximately 
31 mg EPA/kg BW/day (Experiment A) and 27 mg EPA/
kg BW/day (Experiment B). A detailed overview of the 
contents of diets is presented in Table 1. Diets were man-
ufactured by Research Diet Services, Wijk bij Duurstede, 
The Netherlands (Experiment A) and Ssniff Spezialdiäten, 
Soest, Germany (Experiment B) and were stored at −20 °C 
until use, in order to prevent oxidation of lipids. Analysis 
of the diets confirmed the calculated fatty acid composition 
and confirmed that the control diets and the lecithin diet did 
not contain DHA or EPA.
Experimental Design
In both experiments, all rats were provided with the respec-
tive control diet for 2 weeks before starting the interven-
tion. Subsequently, animals were divided into the experi-
mental groups that were matched according to their body 
weight and food intake and were placed on one of the 
experimental diets for 2 weeks (Experiment A) or 3 weeks 
(Experiment B).
Sample Preparation
After the supplementation period, animals were food-
deprived for 3–4 h and euthanized by inhalation of iso-
flurane and subsequent decapitation by guillotine. Trunk 
blood was collected through a funnel into EDTA-containing 
tubes. After centrifugation at 1300×g at 20 °C for 10 min 
(Experiment A) or 1750×g at 4 °C for 10 min (Experiment 
B), plasma and RBC (Experiment B only) were collected 
and analyzed for plasma fatty acid composition (Experi-
ments A and B) and for RBC fatty acid composition and 
free choline (Experiment B only). Plasma sample prepara-
tion in Experiment A was not adequate for choline analy-
sis as plasma free choline is not stable at room tempera-
ture and therefore these results are lacking. Based on the 
results of Experiment A, RBC samples were also collected 
in Experiment B.
Plasma Fatty Acid Composition and Plasma Free 
Choline Analyses
Plasma and RBC total lipid fatty acid composition was 
detected using gas chromatography (GC). Total lipids were 
extracted from plasma and RBC using a modified Bligh 
and Dyer protocol [16] by adding methanol, 1 % EDTA 
solution, and dichloromethane to 100 µL plasma or approx-
imately 150 µL RBC (non-quantitative). After vortexing for 
5 min, samples were centrifuged at 1750×g for 10 min and 
the organic phase (dichloromethane and lipids) was col-
lected. The dichloromethane layer was dried using a Speed-
Vac® concentrator. Next, 2.0 mL methanol and 40 μL con-
centrated sulfuric acid (2 v/v %) were added to the dried 
extract and samples were heated at 100 °C for 60 min 
[17]. After cooling, 2 mL hexane and 0.5 mL 2.5 mol/L 
sodium hydroxide solution were added. Samples were sub-
sequently vortexed and centrifuged for 5 min at 1750×g 
after which the upper layer was collected and dried using a 
SpeedVac®. Dried samples were subsequently dissolved in 
125 μL iso-octane and analyzed by GC (Shimadzu Corpo-
ration, Kyoto, Japan) using flame ionization detection with 
a CP-SIL88 column (50 m × 0.25 mm id. 0.20 μm film 
thickness; Agilent Technologies, Inc., Santa Clara, CA, 
USA). The carrier gas was hydrogen and the make-up gas 
was nitrogen. GC oven temperature settings were as fol-
lows: initial temperature 150 °C for 3.75 min; temperature 
increment to 220 °C at 22 °C/min; and subsequent constant 
temperature of 220 °C for 14.07 min (in-house settings). 
Fatty acids were identified based on retention time using 
an external reference standard (GLC-461, Nu-Chek Prep, 
Inc., Elysian, MN, USA). Peak area was used as a measure 
of relative percent (mol%). An internal standard (1,2-dino-
nadecanoyl-sn-glycero-3-phosphocholine, Avanti Polar 
Lipids, Inc., AL, USA) was used for absolute quantification 
of fatty acids (µmol/L) in plasma. RBC fatty acids were not 
quantitatively pipetted and were therefore not absolutely 
quantified.
High performance liquid chromatography (HPLC) cou-
pled to electrochemical detection of plasma free choline 
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was performed using a commercially available choline 
assay HPLC method from Thermo Fisher Scientific (for-
mer ESA Biosciences, Chelmsford, MA, USA). Briefly, 
after protein precipitation, samples were centrifuged to 
remove proteins. The supernatant was injected into the 
HPLC (Thermo Fisher Scientific, former ESA Biosciences, 
Chelmsford, MA, USA) using a post-column immobilized 
enzyme reactor, in an on-line enzyme reaction to produce 
H2O2, which was detected electrochemically.
Statistical Analyses
All statistical analyses were performed using SPSS (version 
19, SPSS Inc., Chicago, IL, USA). Data were expressed as 
Table 1  Detailed compositions of the experimental diets used in Experiment A and Experiment B
Ingredients (g/100 g diet) Diets Experiment A
Control Lecithin Vegetable DHA oil Vegetable DHA oil + lecithin
Wheat 25.87 25.87 25.87 25.87
Barley 25.00 25.00 25.00 25.00
Semolina 25.00 24.60 25.00 24.60
Soybean meal 8.50 8.50 8.50 8.50
Bentonite 1.00 1.00 1.00 1.00
Whey powder 5.00 5.00 5.00 5.00
Soy oil 1.90 1.90 1.76 1.76
Corn oil 2.20 2.20 1.90 1.90
Coconut fat 0.90 0.90 0.80 0.80
Vegetable algae DHA oil (DHASCO oil) – – 0.54 0.54
Vitamin/mineral mix (including choline) 2.20 2.20 2.20 2.20
CaCO3 1.40 1.40 1.40 1.40
Dicalcium phosphate 0.30 0.30 0.30 0.30
NaCl 0.50 0.50 0.50 0.50
l-Lysine HCl 0.18 0.18 0.18 0.18
dl-Methionine 0.05 0.05 0.05 0.05
Soy lecithin (Emulpur IP) – 0.40 – 0.40
Sum 100.00 100.00 100.00 100.00
Ingredients (g/100 g diet) Diets Experiment B
Control Fish oil Fish oil + lecithin
Cornstarch, pre-gelatinized 34.59 34.59 34.34
Maltodextrin, 10 DE 15.50 15.50 15.50
Sucrose 10.00 10.00 10.00
Dextrose 10.00 10.00 10.00
Cellulose powder 5.00 5.00 5.00
Casein 14.00 14.00 14.00
Soy oil 3.00 3.00 2.25
Corn oil 2.10 1.50 1.50
Coconut fat 0.90 0.70 0.70
Fish oil (Tuna RoPUFA) – 0.80 0.80
Mineral mix (AIN-93M-MX) 3.50 3.50 3.50
Vitamin mix (AIN-93-VX) 1.00 1.00 1.00
Choline chloride (50 %) 0.23 0.23 0.23
l-Cystine 0.18 0.18 0.18
Tert-butylhydroquinone 0.0008 0.0008 0.0008
Soy lecithin (Emulpur IP) – – 1.00
Sum 100.00 100.00 100.00
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means ± SEM. P values <0.05 were considered significant. 
Effects of dietary treatments on body weight and food intake 
were analyzed using repeated-measures ANOVA with Diet 
(Experiment A) or dietary DHA and dietary lecithin (Experi-
ment B) as the between-subject factor(s) and day as the within-
subject factor. Plasma and RBC fatty acids relative and quan-
titative levels (DHA, EPA, total n-3 PUFA and n-6 PUFA) 
and choline concentrations were compared between rats fed 
the different experimental diets using two-way ANOVA with 
dietary DHA and dietary lecithin as between-subject factors 
(Experiment A) or one-way ANOVA (Experiment B). Post 
hoc comparisons were performed where appropriate.
Results
Experiment A
After feeding all animals the control diet for 2 weeks, they 
were divided into four experimental groups that were matched 
according to their body weight and food intake. During the 
supplementation period of 2 weeks body weight was neither 
affected by dietary DHA supplementation (P = 0.55) nor by 
dietary lecithin supplementation (P = 0.72). Also no effects 
on food intake were found (dietary DHA: P = 0.89); dietary 
lecithin: P = 0.99). Dietary DHA supplementation increased 
relative plasma levels of DHA (P < 0.001), EPA (P < 0.001), 
and total n-3 PUFA (P < 0.001), and decreased total n-6 
PUFA (P < 0.001). Plasma levels of DHA (P = 0.20), EPA 
(P = 0.21), and total n-6 PUFA (P = 0.41) were not affected 
by dietary lecithin supplementation, whereas plasma total n-3 
PUFA level (P = 0.007) was affected. Furthermore, interac-
tions between dietary DHA and lecithin supplementation 
were found for plasma DHA (P = 0.039), total n-3 PUFA 
(P = 0.001), and total n-6 PUFA (P = 0.041), however not 
for EPA (P = 0.19). These main and interaction effects indi-
cate that combined dietary supplementation of DHA oil and 
lecithin increased the changes induced by DHA supplemen-
tation alone (Fig. 1a). Quantitative plasma concentrations 
of DHA (P < 0.001), EPA (P < 0.001), and total n-3 PUFA 
(P < 0.001) were also affected by dietary DHA supplementa-
tion, whereas total n-6 PUFA (P = 0.078) was not. No effects 
of dietary lecithin or interactions between dietary DHA and 
lecithin were found when expressing the plasma fatty acid 
levels as quantitative concentrations, although trends were 
apparent (Fig. 1b). Tables 2 and 3 give a complete overview 
of all plasma fatty acids measured, expressed as relative per-
cent levels (Table 2) and quantitative concentrations (Table 3).
Experiment B
Animals were divided into three experimental groups 
that were matched according to their body weights and 
food intake after feeding the animals the control diet 
for 2 weeks. Body weight (P = 0.78) and food intake 
(P = 0.47) did not differ between the experimental groups 
over the course of the 3-week intervention period. Relative 
Fig. 1  Experiment A: effects of dietary supplementation of vegeta-
ble DHA oil, lecithin or the combination of both on a relative percent 
levels (mol%) and b quantitative concentrations (µmol/L) of DHA, 
EPA, total n-3 PUFA, and total n-6 PUFA in plasma of rats. Plasma 
DHA, EPA, total n-3 PUFA, and total n-6 PUFA levels in rats that 
received one of the four experimental diets (control, lecithin, veg-
etable DHA oil, vegetable DHA oil + lecithin) for 2 weeks. Values 
are means, with the SEM represented by vertical bars. Different let-
ters indicate mean values were significantly different (P < 0.05). 
*P = 0.077 vs. vegetable DHA oil + lecithin. n = 6 per experimental 
group
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plasma levels of DHA (P < 0.001), EPA (P < 0.001), total 
n-3 PUFA (P < 0.001), and total n-6 PUFA (P = 0.023) 
were affected by the experimental diets (Fig. 2a). Animals 
fed the fish oil diet displayed increased plasma levels of 
DHA (P < 0.001), EPA (P < 0.001), and total n-3 PUFA 
(P < 0.001), and a decreased plasma total n-6 PUFA level 
(P = 0.031) as compared to the control diet. The increases 
in plasma DHA, EPA, total n-3 PUFA were augmented 
by additional supplementation with lecithin, i.e., plasma 
DHA (P < 0.001), EPA (P < 0.001), and total n-3 PUFA 
Table 2  Experiment A: effects 
of dietary supplementation of 
vegetable DHA oil, lecithin 
or the combination of both on 
plasma fatty acid composition 
(mol%) in rats
Values are means ± SEM
Plasma fatty acids  
(mol% of total fatty acids)
Experiment A
Dietary intervention
Control Lecithin Vegetable DHA oil Vegetable DHA 
oil + lecithin
6:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
8:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
10:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
12:0 0.6 ± 0.2 0.7 ± 0.1 0.7 ± 0.1 0.6 ± 0.1
14:0 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 1.0 ± 0.1
15:0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0
16:0 18.6 ± 0.2 18.6 ± 0.2 19.1 ± 0.3 19.8 ± 0.2
17:0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0
18:0 7.8 ± 0.4 7.6 ± 0.5 7.4 ± 0.4 7.1 ± 0.3
20:0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
22:0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
23:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
24:0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
16:1n-7 1.0 ± 0.1 0.8 ± 0.1 1.1 ± 0.1 1.3 ± 0.2
18:1n-7 2.2 ± 0.1 2.0 ± 0.1 2.1 ± 0.2 2.3 ± 0.2
18:1n-9 11.2 ± 0.5 10.9 ± 0.5 11.1 ± 0.5 11.5 ± 0.4
20:1n-9 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0
22:1n-9 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
24:1n-9 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
20:3n-9 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
18:2n-6 26.5 ± 1.4 28.3 ± 1.0 27.6 ± 0.7 28.1 ± 0.8
18:3n-6 0.4 ± 0.0 0.3 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
20:2n-6 0.6 ± 0.0 0.6 ± 0.0 0.5 ± 0.0 0.6 ± 0.0
20:3n-6 0.6 ± 0.1 0.6 ± 0.0 0.7 ± 0.0 0.8 ± 0.0
20:4n-6 22.4 ± 1.5 21.8 ± 1.5 19.1 ± 1.3 16.6 ± 1.1
22:4n-6 1.1 ± 0.1 1.0 ± 0.1 0.5 ± 0.0 0.6 ± 0.0
22:5n-6 0.6 ± 0.1 0.4 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
24:2n-6 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
18:3n-3 0.7 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 0.9 ± 0.1
18:4n-3 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
20:5n-3 0.2 ± 0.0 0.2 ± 0.0 0.4 ± 0.0 0.5 ± 0.0
22:5n-3 0.6 ± 0.1 0.5 ± 0.0 0.5 ± 0.0 0.6 ± 0.0
22:6n-3 2.2 ± 0.2 2.1 ± 0.1 5.1 ± 0.1 5.7 ± 0.1
Total SFA 29.1 ± 0.2 29.1 ± 0.1 29.4 ± 0.3 29.6 ± 0.2
Total MUFA 14.8 ± 0.5 14.2 ± 0.7 14.7 ± 0.8 15.5 ± 0.6
Total PUFA 56.1 ± 0.5 56.7 ± 0.6 55.9 ± 0.7 54.8 ± 0.6
Total n-3 PUFA 3.8 ± 0.1 3.7 ± 0.1 6.9 ± 0.1 7.7 ± 0.1
Total n-6 PUFA 52.2 ± 0.5 53.0 ± 0.6 49.0 ± 0.7 47.1 ± 0.6
Total fatty acids 100.0 100.0 100.0 100.0
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(P = 0.001) were higher in rats fed the fish oil + lecithin 
diet as compared to those fed the fish oil diet. Express-
ing the plasma fatty acid levels as quantitative concentra-
tions revealed similar effects of the fish oil diet and the 
fish-oil + lecithin diet. Plasma concentrations of DHA 
(P < 0.001), EPA (P < 0.001), total n-3 PUFA (P < 0.001), 
and total n-6 PUFA (P < 0.001) differed between rats 
fed one of the three experimental diets (Fig. 2b). Com-
pared to animals fed the control diet or the Fish oil diet, 
those fed the fish oil + lecithin diet displayed increased 
Table 3  Experiment A: effects 
of dietary supplementation of 
vegetable DHA oil, lecithin 
or the combination of both on 
plasma fatty acid quantitative 
concentrations (µmol/L) in rats
Values are means ± SEM
Plasma fatty  
acids (µmol/L)
Experiment A
Dietary intervention
Control Lecithin Vegetable DHA oil Vegetable DHA 
oil + lecithin
6:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
8:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
10:0 2.3 ± 1.2 2.4 ± 0.9 2.7 ± 0.6 1.9 ± 0.6
12:0 57.9 ± 18.5 70.2 ± 18.6 65.4 ± 10.8 51.6 ± 6.6
14:0 80.5 ± 15.3 80.9 ± 14.2 88.0 ± 10.9 86.9 ± 7.0
15:0 27.0 ± 2.5 29.7 ± 3.0 25.8 ± 2.2 26.8 ± 1.3
16:0 1700.2 ± 160.4 1658.4 ± 152.8 1669.9 ± 130.7 1711.4 ± 92.3
17:0 28.2 ± 1.5 29.3 ± 1.1 26.6 ± 1.6 26.3 ± 1.4
18:0 698.2 ± 35.0 661.1 ± 17.6 639.6 ± 32.0 615.4 ± 38.9
20:0 9.6 ± 1.2 10.2 ± 1.4 9.4 ± 0.8 8.5 ± 0.4
22:0 18.1 ± 1.7 17.6 ± 1.8 14.1 ± 1.1 14.5 ± 0.4
23:0 3.2 ± 0.8 3.2 ± 0.5 2.9 ± 0.5 3.1 ± 0.2
24:0 18.3 ± 1.2 19.5 ± 2.3 17.4 ± 1.0 17.4 ± 1.0
16:1n-7 91.5 ± 14.0 72.3 ± 12.5 95.7 ± 17.9 110.2 ± 17.5
18:1n-7 205.2 ± 21.5 184.1 ± 22.1 189.7 ± 27.5 201.4 ± 17.6
18:1n-9 1031.2 ± 132.8 984.0 ± 125.9 981.3 ± 114.0 989.7 ± 51.5
20:1n-9 26.7 ± 3.7 27.6 ± 4.2 25.9 ± 3.7 24.5 ± 1.0
22:1n-9 2.3 ± 0.5 2.5 ± 0.5 2.1 ± 0.3 2.2 ± 0.3
24:1n-9 11.0 ± 0.4 12.1 ± 1.3 11.1 ± 0.7 12.2 ± 0.7
20:3n-9 6.7 ± 3.3 2.6 ± 0.4 2.8 ± 1.3 2.8 ± 0.6
18:2n-6 2427.3 ± 292.0 2551.9 ± 303.6 2419.2 ± 202.0 2424.5 ± 126.3
18:3n-6 33.6 ± 3.8 27.9 ± 3.0 21.0 ± 2.3 20.4 ± 2.4
20:2n-6 50.6 ± 5.2 51.6 ± 4.0 44.9 ± 5.1 50.0 ± 2.4
20:3n-6 58.5 ± 7.0 56.4 ± 7.3 61.3 ± 6.4 70.4 ± 3.4
20:4n-6 1996.4 ± 110.1 1887.3 ± 74.0 1635.1 ± 72.7 1433.5 ± 116.6
22:4n-6 102.1 ± 12.6 84.5 ± 5.5 48.3 ± 6.0 50.7 ± 2.6
22:5n-6 57.9 ± 11.9 36.6 ± 1.6 16.0 ± 2.9 16.9 ± 1.0
24:2n-6 3.0 ± 0.5 2.9 ± 0.4 2.2 ± 0.3 1.9 ± 0.2
18:3n-3 69.1 ± 13.4 76.1 ± 14.4 77.4 ± 10.1 76.8 ± 6.4
18:4n-3 2.8 ± 1.0 1.5 ± 0.9 1.3 ± 0.9 0.2 ± 0.2
20:5n-3 21.7 ± 1.6 21.7 ± 3.0 33.5 ± 3.4 39.2 ± 3.7
22:5n-3 50.7 ± 5.0 47.2 ± 3.3 43.6 ± 3.4 56.1 ± 5.0
22:6n-3 200.8 ± 21.6 181.8 ± 7.8 449.8 ± 39.1 491.7 ± 25.0
Total SFA 2643.4 ± 223.7 2582.5 ± 211.7 2561.9 ± 180.8 2563.8 ± 132.2
Total MUFA 1367.9 ± 169.1 1282.6 ± 164.0 1305.9 ± 161.6 1340.2 ± 72.6
Total PUFA 5081.3 ± 380.6 5029.9 ± 392.7 4856.2 ± 308.3 4735.0 ± 220.5
Total n-3 PUFA 345.1 ± 30.2 328.3 ± 27.2 605.5 ± 52.6 664.0 ± 35.3
Total n-6 PUFA 4729.4 ± 352.0 4699.0 ± 365.4 4247.9 ± 256.8 4068.2 ± 188.2
Total fatty acids 9092.6 ± 771.1 8895.0 ± 765.0 8724.0 ± 647.0 8639.0 ± 399.5
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plasma concentrations of DHA (P < 0.001 vs. control diet; 
P = 0.022 vs. fish oil diet) and EPA (P < 0.001 vs. con-
trol diet; P = 0.028 vs. fish oil diet). Tables 4 and 5 give 
a complete overview of all plasma fatty acids measured, 
expressed as relative percent levels (Table 4) and quantita-
tive concentrations (Table 5).
Fig. 2  Experiment B: effects of dietary supplementation of fish oil or 
combined dietary supplementation of fish oil and lecithin on a rela-
tive percent levels (mol%) and b quantitative concentrations (µmol/L) 
of DHA, EPA, total n-3 PUFA, and total n-6 PUFA in plasma of rats. 
Plasma DHA, EPA, total n-3 PUFA, and total n-6 PUFA levels in rats 
that received one of the three experimental diets (control, fish oil, fish 
oil + lecithin) for 3 weeks. Values are means, with the SEM repre-
sented by vertical bars. Different letters indicate mean values were 
significantly different (P < 0.025). n = 7–8 per experimental group, 1 
outlier was omitted from the data
Table 4  Experiment B: effects of dietary supplementation of fish 
oil or combined dietary supplementation of fish oil and lecithin on 
plasma fatty acid composition (mol%) in rats
Values are means ± SEM
Plasma fatty acids 
(mol% of total fatty 
acids)
Experiment B
Dietary intervention
Control Fish oil Fish oil + lecithin
6:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
8:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
10:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
12:0 0.4 ± 0.1 0.2 ± 0.0 0.2 ± 0.0
14:0 1.2 ± 0.1 0.9 ± 0.0 1.0 ± 0.1
15:0 0.2 ± 0.0 0.2 ± 0.0 0.3 ± 0.0
16:0 21.2 ± 0.2 22.4 ± 0.2 22.9 ± 0.3
17:0 0.1 ± 0.0 0.1 ± 0.0 0.2 ± 0.0
18:0 6.8 ± 0.4 7.2 ± 0.2 7.2 ± 0.3
20:0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
22:0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
23:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
24:0 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0
16:1n-7 2.8 ± 0.3 2.4 ± 0.1 2.4 ± 0.3
18:1n-7 3.5 ± 0.2 2.9 ± 0.1 2.7 ± 0.1
18:1n-9 13.3 ± 0.7 12.5 ± 0.2 11.6 ± 0.5
20:1n-9 0.2 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
22:1n-9 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
24:1n-9 0.1 ± 0.0 0.1 ± 0.0 0.2 ± 0.0
20:3n-9 0.2 ± 0.0 0.1 ± 0.0 0.2 ± 0.0
18:2n-6 26.4 ± 0.7 27.4 ± 0.5 27.6 ± 0.4
18:3n-6 0.4 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
20:2n-6 0.3 ± 0.0 0.3 ± 0.0 0.2 ± 0.0
20:3n-6 0.4 ± 0.0 0.5 ± 0.0 0.5 ± 0.0
20:4n-6 18.4 ± 1.1 14.8 ± 0.5 14.3 ± 0.8
22:4n-6 0.3 ± 0.1 0.4 ± 0.1 0.3 ± 0.1
22:5n-6 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
24:2n-6 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
18:3n-3 0.9 ± 0.0 1.0 ± 0.0 0.8 ± 0.1
18:4n-3 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
20:5n-3 0.4 ± 0.0 1.5 ± 0.1 1.8 ± 0.1
22:5n-3 0.5 ± 0.0 0.7 ± 0.0 0.8 ± 0.0
22:6n-3 1.2 ± 0.1 3.3 ± 0.2 4.0 ± 0.1
Total SFA 30.6 ± 0.3 31.7 ± 0.3 32.4 ± 0.3
Total MUFA 19.8 ± 1.1 18.0 ± 0.3 16.9 ± 0.9
Total PUFA 49.5 ± 1.0 50.3 ± 0.2 50.7 ± 0.9
Total n-3 PUFA 2.9 ± 0.1 6.5 ± 0.2 7.3 ± 0.2
Total n-6 PUFA 46.4 ± 0.9 43.7 ± 0.1 43.2 ± 1.0
Total fatty acids 100.0 100.0 100.0
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In RBC, similar differences in levels of DHA, EPA, n-3 
PUFA, and n-6 PUFA between the experimental groups were 
found as obtained in plasma. Relative RBC levels of DHA 
(P < 0.001), EPA (P < 0.001), total n-3 PUFA (P < 0.001), 
and total n-6 PUFA (P < 0.001) also were affected by the 
experimental diets (Fig. 3). Compared to animals fed the 
control diet or the fish oil diet, those fed the fish oil + leci-
thin diet displayed increased RBC levels of DHA (P < 0.001 
vs. control diet; P = 0.009 vs. fish oil diet), EPA (P < 0.001 
vs. control diet; P = 0.006 vs. fish oil diet), and total n-3 
PUFA (P < 0.001 vs. control diet; P = 0.004 vs. fish oil diet). 
Table 6 gives a complete overview of all RBC fatty acids 
measured, expressed as relative percent levels.
Plasma free choline concentration was also affected 
by the experimental diets (P = 0.030, Fig. 4). In animals 
receiving the lecithin-containing diet, plasma free choline 
concentration was higher as compared to those receiv-
ing the diets without lecithin (P = 0.049 vs. control diet; 
P = 0.012 vs. fish oil diet).
Discussion
The present experiments indicate that dietary crude leci-
thin can increase the systemic availability of dietary DHA 
with combined intake. Dietary supplementation of lecithin, 
which itself does not contain any DHA, increased levels of 
DHA, EPA, and total n-3 PUFA in plasma and RBC, and 
Table 5  Experiment B: effects of dietary supplementation of fish 
oil or combined dietary supplementation of fish oil and lecithin on 
plasma fatty acid quantitative concentrations (µmol/L) in rats
Values are means ± SEM
Plasma fatty  
acids (µmol/L)
Experiment B
Dietary intervention
Control Fish oil Fish oil +  
lecithin
6:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
8:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
10:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
12:0 40.3 ± 13.8 14.9 ± 2.3 12.9 ± 2.8
14:0 104.2 ± 19.2 61.3 ± 4.5 62.7 ± 7.5
15:0 15.0 ± 1.1 16.0 ± 0.9 17.0 ± 1.4
16:0 1726.0 ± 111.3 1462.0 ± 50.1 1471.8 ± 81.1
17:0 9.0 ± 1.3 9.7 ± 2.2 11.6 ± 1.3
18:0 544.7 ± 26.4 470.0 ± 18.4 456.3 ± 13.8
20:0 6.9 ± 0.7 6.3 ± 0.4 6.7 ± 0.6
22:0 18.5 ± 1.1 14.1 ± 1.0 14.8 ± 1.0
23:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
24:0 22.2 ± 0.7 18.5 ± 0.8 21.5 ± 1.2
16:1n-7 230.3 ± 36.0 155.7 ± 7.8 158.2 ± 23.6
18:1n-7 282.9 ± 29.9 187.8 ± 7.7 176.0 ± 16.3
18:1n-9 1101.0 ± 124.7 815.0 ± 38.0 750.9 ± 68.1
20:1n-9 12.6 ± 1.9 8.3 ± 0.5 5.9 ± 1.1
22:1n-9 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
24:1n-9 9.3 ± 0.5 9.5 ± 0.2 9.8 ± 0.8
20:3n-9 17.6 ± 1.3 9.3 ± 0.8 9.6 ± 0.9
18:2n-6 2151.2 ± 165.7 1793.2 ± 85.1 1768.8 ± 96.2
18:3n-6 29.6 ± 1.2 16.0 ± 1.6 14.0 ± 1.3
20:2n-6 27.4 ± 2.4 17.4 ± 1.4 15.9 ± 1.3
20:3n-6 35.8 ± 2.2 34.2 ± 1.7 33.1 ± 2.1
20:4n-6 1463.9 ± 45.1 963.2 ± 45.5 902.7 ± 16.3
22:4n-6 28.1 ± 9.0 26.9 ± 10.4 17.0 ± 6.9
22:5n-6 9.1 ± 2.9 6.6 ± 0.4 3.7 ± 1.4
24:2n-6 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
18:3n-3 71.9 ± 8.5 63.7 ± 3.9 50.6 ± 8.4
18:4n-3 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
20:5n-3 33.8 ± 2.7 96.6 ± 5.0 115.0 ± 7.3
22:5n-3 37.1 ± 2.0 46.7 ± 2.8 49.2 ± 5.3
22:6n-3 92.1 ± 5.0 214.5 ± 11.2 257.7 ± 16.9
Total SFA 2486.9 ± 156.9 2072.6 ± 66.0 2075.2 ± 96.7
Total MUFA 1636.1 ± 187.7 1176.4 ± 52.0 1100.9 ± 107.6
Total PUFA 3997.7 ± 189.1 3288.2 ± 130.7 3237.4 ± 139.2
Total n-3 PUFA 234.9 ± 10.9 421.5 ± 18.7 472.5 ± 35.0
Total n-6 PUFA 3745.2 ± 178.2 2857.4 ± 115.9 2755.2 ± 106.6
Total fatty acids 8120.6 ± 510.0 6537.3 ± 243.6 6413.5 ± 327.5
Fig. 3  Experiment B: effects of dietary supplementation of fish oil or 
combined dietary supplementation of fish oil and lecithin on relative 
percent levels (mol%) of DHA, EPA, total n-3 PUFA, and total n-6 
PUFA in RBC of rats. RBC DHA, EPA, total n-3 PUFA, and total n-6 
PUFA levels in rats that received one of the three experimental diets 
(control, fish oil, fish oil + lecithin) for 3 weeks. Values are means, 
with the SEM represented by vertical bars. Different letters indicate 
mean values were significantly different (P < 0.025). n = 8 per exper-
imental group
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decreased levels of total n-6 PUFA in plasma of rats fed 
DHA oil-containing diets. Thus, while dietary lecithin sup-
plementation alone did not affect DHA levels in plasma and 
RBC, lecithin further increased the rise in DHA induced by 
dietary DHA supplementation (vs. control diets) with up to 
61 % (relative levels) and 47 % (quantitative concentration) 
in plasma, and with 18 % (relative level) in RBC. Further-
more, dietary lecithin, being a source of PtdCho, increased 
plasma choline concentration with 11 %.
Dietary supplementation of moderate levels of DHA (i.e., 
0.2 %), either as vegetable algae oil or as fish oil, affected 
relative and quantitative plasma levels and relative RBC fatty 
Table 6  Experiment B: effects 
of dietary supplementation of 
fish oil or combined dietary 
supplementation of fish oil 
and lecithin on RBC fatty acid 
composition (mol%) in rats
Values are means ± SEM
RBC fatty acids  
(mol% of total fatty acids)
Experiment B
Dietary intervention
Control Fish oil Fish oil + lecithin
6:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
8:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
10:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
12:0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
14:0 0.6 ± 0.0 0.5 ± 0.0 0.5 ± 0.0
15:0 0.2 ± 0.0 0.3 ± 0.0 0.3 ± 0.0
16:0 34.7 ± 0.3 36.4 ± 0.4 35.5 ± 0.3
17:0 0.3 ± 0.0 0.3 ± 0.0 0.4 ± 0.0
18:0 10.1 ± 0.3 10.1 ± 0.2 10.4 ± 0.2
20:0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
22:0 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.0
23:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
24:0 1.1 ± 0.0 1.0 ± 0.0 1.1 ± 0.0
16:1n-7 0.9 ± 0.1 0.8 ± 0.0 0.8 ± 0.1
18:1n-7 3.5 ± 0.1 3.2 ± 0.1 3.0 ± 0.1
18:1n-9 7.2 ± 0.2 7.0 ± 0.1 6.6 ± 0.2
20:1n-9 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
22:1n-9 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
24:1n-9 0.7 ± 0.0 0.7 ± 0.0 0.7 ± 0.0
20:3n-9 0.2 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
18:2n-6 14.2 ± 0.5 14.5 ± 0.3 15.4 ± 0.3
18:3n-6 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
20:2n-6 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.0
20:3n-6 0.4 ± 0.0 0.5 ± 0.0 0.5 ± 0.0
20:4n-6 19.6 ± 0.3 16.6 ± 0.2 16.5 ± 0.3
22:4n-6 1.6 ± 0.0 1.2 ± 0.0 1.2 ± 0.0
22:5n-6 0.3 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
24:2n-6 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
18:3n-3 0.2 ± 0.0 0.3 ± 0.0 0.2 ± 0.0
18:4n-3 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
20:5n-3 0.1 ± 0.0 0.5 ± 0.0 0.6 ± 0.0
22:5n-3 1.3 ± 0.0 1.4 ± 0.0 1.4 ± 0.0
22:6n-3 1.5 ± 0.1 3.1 ± 0.1 3.4 ± 0.0
Total SFA 47.5 ± 0.4 49.2 ± 0.3 48.7 ± 0.3
Total MUFA 12.5 ± 0.4 11.9 ± 0.2 11.3 ± 0.3
Total PUFA 40.1 ± 0.3 38.9 ± 0.3 40.0 ± 0.3
Total n-3 PUFA 3.2 ± 0.1 5.3 ± 0.1 5.6 ± 0.1
Total n-6 PUFA 36.8 ± 0.3 33.6 ± 0.3 34.3 ± 0.3
Total fatty acids 100.0 100.0 100.0
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acid levels as expected. Previous studies, both experimental 
[4, 5, 18–21] and clinical [3, 22, 23], repeatedly demonstrated 
that plasma and RBC levels of DHA increase relatively fast in 
a dose-dependent manner after oral administration of DHA. 
In human, steady state plasma concentrations of DHA after 
supplementation is reached within 1 week up to 1 month, 
whereas for RBC this takes several months [3, 22]. In rats, 
fatty acid levels in plasma and RBC represents dietary intake 
of fats over a relatively short-term period of 1–4 weeks [24]. 
Hence, the plasma and RBC samples from the rats in the cur-
rent study reflect the effects of the changes in dietary pattern 
(i.e., changes dietary DHA-containing oils and lecithin con-
tent) over the weeks of the applied supplementation period.
Dietary crude lecithin is a source of active compounds as 
it is digested into fatty acids, lysophospholipids, phospha-
tidic acid, glycerol, monoglycerides, and other compounds, 
including choline and ethanolamine. These digestion prod-
ucts are subsequently absorbed and further metabolized. For 
example, the intake of lecithin has been shown to increase 
serum levels of choline in humans [25] and rats [26]. In 
Experiment B, it was confirmed that lecithin supplementa-
tion increases plasma choline concentration in rats.
Systemic DHA is known to be transferred across the 
blood–brain barrier, as shown in both experimental [27, 28] 
and clinical studies [6, 29, 30]. In fact, dietary supplemen-
tation with DHA (in various formulas) has repeatedly been 
shown to affect membrane composition [5, 18, 31–39], 
thereby influencing its biophysical properties. A high level 
of n-3 PUFA in neuronal membranes is associated with 
favorable effects on numerous membrane-dependent pro-
cesses and thus neuronal functioning [1, 2]. Likewise, small 
increases in plasma choline can exert significant effects on 
brain choline levels [40], and in fact, lecithin intake has 
been shown to increase both plasma and brain choline lev-
els in the rat [26]. Brain choline levels in turn control the 
rates at which it is utilized to form acetylcholine [41, 42]. 
In addition, DHA, EPA and choline [43–45] are known pre-
cursors for phospholipid synthesis needed for membrane 
formation and integrity. By increasing the systemic avail-
ability of dietary DHA and by increasing the systemic lev-
els of choline, dietary lecithin putatively leads to increased 
uptake of DHA and choline into the brain, with subsequent 
effects on neuronal membrane formation and function.
Fig. 4  Experiment B: effects of dietary supplementation of fish oil 
or combined dietary supplementation of fish oil and lecithin on rat 
plasma free choline concentration (µmol/L). Plasma free choline con-
centration in rats that received one of the three experimental diets for 
3 weeks (control, fish oil, fish oil + lecithin). Values are means, with 
the SEM represented by vertical bars. Different letters indicate mean 
values were significantly different (P < 0.05). n = 8 per experimental 
group
Fig. 5  Schematic representation of the effects of dietary phospho-
lipids on enhancing the absorption of dietary n-3 PUFA from the 
gut into the enterocytes and the lymph. Dietary phospholipids may 
increase the bioavailability of dietary n-3 PUFA by facilitating emul-
sification (1) and by increasing chylomicron formation (2). Figure is 
adapted from van Wijk et al. [54] with permission from IOS press. PL 
dietary phospholipids
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The effects of lecithin supplementation on the systemic 
availability of dietary n-3 PUFA might be explained by 
an increased absorption from the gut into the enterocytes 
and the lymph. Dietary phospholipids could enhance the 
absorption of n-3 PUFA from the gut, since they are known 
to facilitate the emulsification of dietary fat in the lumen 
and subsequent micelle formation for absorption into the 
enterocytes [8, 46]. Moreover, dietary phospholipids may 
increase the intestinal uptake of fat by increasing the for-
mation of chylomicrons in enterocytes and their secretion 
into the lymph [7, 10]. In the current study, the highest per-
centage increases in DHA were found in Experiment B in 
which a higher dose of crude lecithin was used (0.4 % in 
Experiment A and 1.0 % in Experiment B), possibly indi-
cating dose-dependency. Figure 5 shows a schematic repre-
sentation of these effects of dietary phospholipids.
Several investigators have previously attempted to 
demonstrate additive effects of lecithin or phospholipids 
or other emulsifiers on the bioavailability of triglycerides 
after oral intake in various models and using different 
approaches. Various studies thereby focused on the effects 
of pre-emulsification of oil with various emulsifiers, includ-
ing lecithin [13–15, 47–49]. These studies distinctly show 
that single oral administration of pre-emulsified oil has a 
better bioavailability than non-emulsified oil. For exam-
ple, Nishimukai et al. showed that duodenal infusion of an 
emulsion of triglycerides plus lecithin induces higher portal 
plasma triglycerides as compared to infusion of triglycer-
ides alone [10]. In one study, the incorporation of radiola-
beled DHA into various rat tissues were measured after a 
single dose of orally gavaged radiolabeled DHA, with or 
without administration of phospholipids (without emulsifi-
cation), and showed no differential effects on the level of 
radiolabeled DHA in whole blood after 24 h [11]. Studies 
examining the effects of combined dietary supplementation 
of lecithin or phospholipids and (non-emulsified) triglycer-
ides on systemic availability of triglycerides are scarcer. An 
experiment in fish (carps) demonstrated stimulated intes-
tinal triglyceride uptake into plasma when dietary triglyc-
erides were combined with dietary phospholipids [9]. In 
contrast, Lim et al. did not find increased amounts of DHA 
in plasma after combined dietary supplementation with 
DHA and phospholipids compared to supplementation with 
DHA alone [18]. However, in this study DHA content of 
the diet with both DHA and phospholipid was half of the 
DHA diet, which makes the diets’ efficacy impossible to 
compare. Other investigators have tried to show superiority 
of DHA-containing phospholipids (i.e., phospholipids with 
DHA as one of the fatty acid chains) over DHA-contain-
ing triglycerides to increase tissue levels of DHA in both 
preclinical and clinical experiments [11, 21, 50–53]. None 
of these studies showed differences in plasma DHA levels 
after supplementing with DHA-containing phospholipids 
as compared to DHA-containing triglycerides, although 
some studies did reveal superiority of DHA-containing 
phospholipids on DHA levels in other tissues, such as RBC 
[21, 53] and the brain [11, 53]. Nevertheless, most studies 
concluded that the absorption into the bloodstream is inde-
pendent of type of DHA (as phospholipid or as triglycer-
ide). The present study actually shows that supplementation 
of lecithin, i.e., phospholipids, further increases the rise in 
systemic DHA induced by dietary DHA supplementation.
It should be noted that the present experiments were 
each conducted under different experimental conditions. 
Most important differences were the amounts of lecithin 
supplemented to the diet (0.4 vs. 1.0 %), supplementation 
periods (2 vs. 3 weeks), DHA-containing oils (vegetable 
algae DHA oil vs. fish oil), rat strain (Wistar vs. Sprague–
Dawley), diet base (grain-based vs. AIN-93M-based), and 
diet manufacturer (Research Diet Services and Ssniff Spe-
zialdiäten). However, despite the differences in experimen-
tal conditions, the results from both experiments are highly 
consistent with some small differences in effects sizes. For 
example, in Experiment B a significant additional effect 
of dietary lecithin supplementation on top of dietary DHA 
supplementation on relative plasma DHA level and quanti-
tative plasma DHA concentration were observed, whereas 
in Experiment A this additional effect was only observed 
on relative plasma DHA level. Overall, the experiments 
demonstrate a substantial effect of combined dietary sup-
plementation of lecithin and DHA on plasma and RBC lev-
els of DHA, EPA, n-3 PUFA, and n-6 PUFA.
Important to consider when extrapolating the current 
results to a human setting is the physiological difference 
between rats and human. Rats have a continuous release 
of hepatic bile as opposed to burst release of gall bile in 
humans. Whether this physiological difference has an 
impact on the effects of lecithin supplementation is diffi-
cult to predict. In addition, for a better interpretation of the 
current results, future preclinical experiments should also 
incorporate measurements in other important lipid pools 
that either influence the plasma lipid pool (e.g., the liver) or 
that are influenced by the plasma lipid pool (e.g., the brain).
Dietary DHA-containing oils and crude lecithin have 
synergistic effects on increasing plasma and RBC n-3 
PUFA levels, including DHA and EPA. By increasing the 
systemic availability of dietary DHA, dietary lecithin may 
increase the efficacy of DHA supplementation when their 
intake is combined. Lecithin itself also raises plasma cho-
line concentration. Therefore, combined supplementation 
of lecithin and DHA may be relevant in conditions that are 
associated with lower levels of plasma DHA and choline.
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